Rob ten Hoedt Joins Berlin Heals as New Chairman
Berlin Heals Holding AG is excited to announce the appointment of Rob ten Hoedt as the newly appointed Chairman of the Board of Directors. With a rich background in healthcare and medical technology, Mr. ten Hoedt's expertise will provide a fresh momentum for the company's future initiatives.
Significance of Mr. ten Hoedt’s Appointment
Marko Bagaric, Co-founder and Member of the Board, expressed his enthusiasm regarding the new addition. “We are thrilled to welcome someone of Rob ten Hoedt's caliber to the Board,” he stated, highlighting the potential positive impact his extensive experience will have on their operations as they strive to enhance their services and solutions in the healthcare space.
Background and Experience of Rob ten Hoedt
Rob ten Hoedt brings over 30 years of global leadership experience in the medical technology and healthcare sectors. His most recent role was as Executive Vice President and President for Global Regions at Medtronic. His career also includes significant leadership roles at Vitatron and Urologix, among others. Rob holds a degree in Commercial Economy from the H.E.A.O. in the Netherlands and a Master's in Marketing from NIMA Business School.
Contributions to the Board
Expressing his excitement about joining the board, Mr. ten Hoedt stated, “I am very excited to join the Board of Directors at Berlin Heals Holding AG and to contribute to its revolutionary new therapy in Heart Failure. Together, we will strive to bring the life-changing benefits of the C-MIC device to patients worldwide. A thrilling time lies ahead, and it is an honor to be part of it.”
Focus on Innovation and Growth
John Brumfield, the Chief Executive Officer at Berlin Heals Holding AG, conveyed his confidence in Mr. ten Hoedt’s leadership potential. He stated, “We are delighted to welcome Rob ten Hoedt as our new Chairman of the Board as we enter a pivotal year for Berlin Heals. His knowledge, leadership experience, and genuine passion for innovation will play an instrumental role in shaping our strategy and driving further growth.”
Understanding C-MIC Therapy
Cardiac Microcurrent (C-MIC) Therapy represents a groundbreaking advancement in treating Heart Failure. This therapy involves a fully implantable medical device that utilizes two electrodes linked to an implantable generator, delivering a steady stream of direct microcurrent to the affected heart area. Studies have suggested that this direct current can significantly reduce inflammation and remap heart structure, leading to improvements in cardiac function and symptom relief.
A New Approach to Treat Heart Failure
Previously, the essential procedure requiring C-MIC therapy involved minimally invasive surgery where a cardiothoracic surgeon would place an electrode on the exterior of the heart. The innovative less invasive method now allows for the implantation of the device via catheterization in outpatient settings, making treatment more accessible and less taxing on patients.
Overview of Heart Failure
Heart failure is a serious condition that occurs when the heart becomes impaired and cannot sufficiently meet the body's blood flow requirements. Common symptoms include shortness of breath, fatigue, and palpitations, which significantly affect daily living. As a progressive disease, it leads to frequent hospitalizations and increased healthcare costs, affecting around 64 million people globally. The prospects of developing heart failure increase drastically, impacting one in four individuals at some point in their lives.
The Financial Impact of Heart Failure
With the costs associated with heart failure care expected to reach approximately $858 billion annually by 2050, it is imperative to find effective treatments. Currently, heart failure remains a leading cause of mortality, surpassing that of many forms of cancer, highlighting the urgent need for further research and effective therapeutic options.
About Berlin Heals Holding AG
Berlin Heals Holding AG is committed to revolutionizing heart failure treatment through its innovative therapies. Following a successful First-In-Human study in recent years, along with consistent long-term results and a randomized controlled trial wrapping up, the company is poised to enhance patient care through advanced, less invasive procedures. Operating from Zug, Switzerland, with branches in Germany and the United States, Berlin Heals is dedicated to pushing medical boundaries for better health outcomes.
Frequently Asked Questions
What is the significance of Rob ten Hoedt's appointment?
Rob ten Hoedt's extensive background in healthcare leadership positions him as a potential catalyst for innovative growth at Berlin Heals.
What is C-MIC Therapy?
C-MIC Therapy is a novel treatment involving a fully implantable device that delivers microcurrents to improve heart function.
How does heart failure impact patients?
Heart failure limits daily activities, leading to severe symptoms like fatigue and breathlessness, greatly affecting quality of life.
Why is heart failure a pressing global issue?
With an increasing prevalence and rising treatment costs, effective interventions are crucial as heart failure significantly impacts patient mortality and healthcare systems.
Where is Berlin Heals based?
Berlin Heals Holding AG is headquartered in Zug, Switzerland, and operates subsidiaries in Germany and the USA.
